RxDoctor Payments Data

Pauline Wilks, APRN

Family · South Windsor, CTNPI 1861969966

Payments from drug & device makers

$8,137in general payments, 2019–2025

Across 380 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • ANI Pharmaceuticals, Inc.$1K
  • AbbVie$907
  • Johnson & Johnson$758
  • UCB, Inc.$687
  • Mallinckrodt Hospital Products Inc.$434
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$7,95398%
  • Education$1842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,137 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$18,162
Medicare patients
120
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab64$485,171
Enbrel SureclickEtanercept25$180,549
Orencia ClickjectAbatacept14$74,922
Actemra ActpenTocilizumab11$32,558
MethotrexateMethotrexate Sodium98$2,480
Hydroxychloroquine Sulfate66$2,092
Leflunomide45$1,600
Prednisone157$1,288
Gabapentin66$781
Diclofenac Sodium37$751
Tramadol Hcl73$727
Sulfasalazine27$665
Pregabalin29$436
Colchicine14$436
Methylprednisolone20$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Colchicine$25$43614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in South Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →